by Jason Simpkins
GW Pharmaceuticals (Nasdaq: GWPH) saw its stock shoot up more than 130% yesterday.
The U.K.-based company is a producer of cannabinoid (read: marijuana) based medicine. And on Monday, it reported that one of its drugs successfully reduced seizures in children suffering from epilepsy.
The drug, Epidiolex, is a liquid formulation of highly purified CBD extract that targets Dravet syndrome – a form of childhood epilepsy that hits babies before the first birthday.
In the phase III trial, patients that received Epidiolex experienced a median reduction in monthly convulsive seizures of 39%, compared to a 13% reduction for the placebo.